The present invention belongs to the field of pharmaceutical industry and relates to novel crystalline omeprazole sodium ethanol solvate and to the process for its preparation which acts as intermediary compound to the processes for its conversion into different crystalline forms first of all to a known omeprazole sodium form A with low amount of residual solvents i.e. less than 0.5% by weight of residual solvent. The present invention also relates to novel crystalline omeprazole sodium form E a...

A precursor phase of the magnesium tetrahydrate salt of an omeprazole enantiomer and also processes for preparing it and its use for the preparation of the magnesium tetrahydrate salt are described. Crystals of the magnesium tetrahydrate salt thus obtained and their uses especially in the synthesis of the dihydrate form A of the magnesium salt of the enantiomer or as medicament are also disclosed.

A pharmaceutical formulation of a gastric proton pump inhibitor with the exception of omeprazole is disclosed. The formulation is in the form of microgranules insoluble in gastric fluid having improved stability over time. The formulation comprises several hydrophobic substances chosen in order to increase the stability of the active principle while obtaining the desired dissolution profile.

Disclosed are a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases which has high optical purity theremostability solubility and nonhygroscopicity a method for preparing same and a pharmaceutical composition containing same.

PCT No. PCT/SE98/00922 Sec. 371 Date Jun. 8 1998 Sec. 102(e) Date Jun. 8 1998 PCT Filed May 18 1998 PCT Pub. No. WO98/53803 PCT Pub. Date Dec. 3 1998An enteric coated oral pharmaceutical formulation comprising as active ingredient a compound selected from the group of omeprazole an alkaline salt of omeprazole the (-)-enantiomer of omeprazole and an alkaline salt of the (-)-enantiomer of omeprazole wherein the formulation comprises a core material of the active ingredient and optionally an alkali...

Disclosed are a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases which has high optical purity thermostability solubility and nonhygroscopicity a method for preparing same and a pharmaceutical composition containing same.

Disclosed are a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, thermostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition containing same.

A novel process for the preparation of omeprazole and its enantiomers such as esomeprazole as well as the preparation of related 2-(2-pyridinylmethyl-sulphinyl)-1H-benzimidazoles including pantoprazole lansoprazole and rabeprazole as recemates or single enantiomers and their alkali or alkaline salts has been developed. The novel process involves the surprising discovery that protection of the free-base benzimidazole sulfoxide (e.g. omeprazole or esomeprazole) by reaction with an alkyl aryl or ar...

A novel process for the preparation of omeprazole and its enantiomers such as esomeprazole as well as the preparation of related 2-(2-pyridinylmethyl-sulphinyl)-1H-benzimidazoles including pantoprazole lansoprazole and rabeprazole as recemates or single enantiomers and their alkali or alkaline salts has been developed. The novel process involves the surprising discovery that protection of the free-base benzimidazole sulfoxide (e.g. omeprazole or esomeprazole) by reaction with an alkyl aryl or ar...